Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Annovis Bio ( (ANVS) ) has issued an announcement.
On May 20, 2026, Annovis Bio entered an underwriting agreement with Canaccord Genuity for a public offering of 7,895,000 common shares and accompanying warrants to purchase up to 7,105,500 shares, priced at a combined $1.90 per share and nine-tenths warrant. The warrants are immediately exercisable at $2.25 per share and expire six years after issuance, with the deal expected to generate roughly $15 million in gross proceeds and close around May 21, 2026, subject to customary conditions.
The company said it plans to use the net proceeds to fund continued clinical development of its lead drug buntanetap in studies for Alzheimer’s and Parkinson’s disease, as well as for working capital and general corporate purposes. The offering, launched in a May 19, 2026 press release and subsequently priced on May 20, 2026, underscores Annovis’s reliance on equity financing to advance its late-stage neurodegeneration pipeline, a move that may dilute existing shareholders while supporting critical Phase 3 trial execution.
The most recent analyst rating on (ANVS) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.
Spark’s Take on ANVS Stock
According to Spark, TipRanks’ AI Analyst, ANVS is a Neutral.
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and sustained negative cash flow with heightened TTM deterioration). Technicals are mixed with neutral momentum but a weak longer-term trend, while valuation metrics provide limited support due to non-meaningful P/E and no dividend. Recent financing improves runway for trials but adds dilution risk, keeping the overall profile below average.
To see Spark’s full report on ANVS stock, click here.
More about Annovis Bio
Annovis Bio, Inc., headquartered in Malvern, Pa., is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its lead candidate, buntanetap, is an investigational once-daily oral therapy that targets the translation of multiple neurotoxic proteins via a specific RNA-based mechanism to slow or halt disease progression.
The company aims to improve cognitive and motor function by addressing underlying drivers of neurodegeneration, positioning itself within the competitive neuro-focused biotech segment. Annovis is listed on the NYSE under the ticker ANVS and concentrates its pipeline and capital allocation on late-stage clinical development of buntanetap for major neurodegenerative indications.
Average Trading Volume: 869,010
Technical Sentiment Signal: Sell
Current Market Cap: $71.03M
See more insights into ANVS stock on TipRanks’ Stock Analysis page.